Vanderbilt Vaccine Center

October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

By Bill Snyder
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

By Bill Snyder
September 8, 2021

VUMC antibodies help neutralize two deadly viruses: study

Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.

By Bill Snyder
August 23, 2021

‘DNA’ podcast Season 2 explores COVID, science and trust in communities

By Holly Fletcher
August 20, 2021

COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study

A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.

By Bill Snyder
August 19, 2021

Team isolates antibodies that target alphaviruses

A multi-institutional team led by researchers at Vanderbilt University Medical Center has isolated monoclonal antibodies that in laboratory and animal studies prevented infection by alphaviruses, including the often-lethal Eastern equine encephalitis virus (EEEV).

By Bill Snyder
August 10, 2021

Shared antibodies may push COVID-19 variants: VUMC study

Researchers at Vanderbilt University Medical Center have found that people recovering from COVID-19 and those vaccinated against the causative virus, SARS-CoV-2, produce identical clones, or groups, of antibody-producing white blood cells.
By Bill Snyder
July 16, 2021

Study identifies monoclonal antibodies that may neutralize many norovirus variants

Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract.
By Bill Snyder
June 22, 2021

Combination antibody therapies should retain effectiveness against emerging COVID-19 variants: study

Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature.
By Bill Snyder
May 24, 2021

Therapeutic antibodies for hantavirus

Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential.
By Bill Snyder
April 12, 2021

VUMC team’s COVID-19 research featured on “60 Minutes”

James Crowe, MD, and members of his lab at Vanderbilt University Medical Center who have pioneered rapid development of monoclonal antibody treatments for life-threatening viral diseases including COVID-19, were featured Sunday on a CBS News 60 Minutes segment titled “The Last Pandemic.”
By Bill Snyder
April 12, 2021

Crowe receives SEC Faculty Achievement Award

James Crowe Jr., MD, a physician-scientist on the front lines of global research to eliminate human susceptibility to COVID-19 and other illnesses, is Vanderbilt University’s winner of the 2021 Southeastern Conference Faculty Achievement Award.
By VUMC News and Communications
April 6, 2021

U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC

The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.
By Bill Snyder
1 2 3 4 5 6 … 14